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Introduction
IL-12, a heterodimeric cytokine, is composed of two subunits, p40 and p35. This cytokine is produced mainly by monocytes/macrophages and promotes the development and activity of cytotoxic T-lymphocytes, including natural killer cells, lymphokineactivated killer cells, and macrophages. Consequently, IL-12 is now recognized as a critical cytokine for intracellular pathogens in immune responses 1 . IL-12 has also been shown to have an adjuvant activity 2 . Salmonella strains are intracellular pathogens inducing Th1 and Th2 immune responses 3, 4 . The immune response to Salmonella infection has been studied extensively in mice. A child with Il-12 deficiency may be predisposed to severe infections due to poorly virulent Salmonella. It is suggested that IL-12 is essential to and appears specific for protective immunity to intracellular bacteria, such as Salmonella.
Salmonella species are a common cause of enteric infection in humans and are associated with significant mortality all over the world. Salmonella strains were first used as a bioterror agent in 1984 5 . This agent was a new, modified strain of existing bacteria. Similarly to these Salmonella strains, bioterror agents are modified to evade detection by existing diagnostic, as well as treatment measures 6 . In the age of the bioterror menace, bioterror agents could be modified to cause outbreaks of infectious diseases which cannot be cured with existing treatments. The development of rapid and new treatment measures against unknown and modified bioterror agents is necessary to cope with this bioterror situation 1, 2, 3 . Existing vaccines, however, are developed by the attenuation of pathogens through the genetic modification process. In addition, vaccines were prepared from the DNA of pathogens or from killed pathogens 4, 5, 6 . These vaccine development processes were extremely time-consuming. Furthermore, existing vaccines are useless for protecting the public and the military health systems against bioterror that requires rapid, new vaccine development against pathogens used as bioweapons during wartime 7, 8 . We used a wild-type organism without the chemical and biological attenuation process. The use of the wild-type strain can shorten the vaccine development process. Instead of the attenuation of pathogens or other processes required for the preparation of vaccine, we used a means of stimulating the host defense system at infected sites to prepare the vaccine. We speculated that the host defense system could play a more crucial role in the prevention of infectious agents than the virulence of unknown infectious agents. Thus, we postulated that the infection of this lethal strain with host-stimulating cytokine might induce protective immunity.
In this study, we investigated the possibility of vaccine development using IL-12 against virulent Salmonella. We used the host defense system activated by cytokine IL-12. The highly virulent Salmonella strain (Salmonella typhimurium UK-1) was transformed with cytokine-expressing plasmids. These live wild-type pathogens were used as vaccine strains without other biological and genetic attenuating processes.
To test this hypothesis, we applied this concept to the preparation of Salmonella typhimurium vaccine in mice. S. typhimurium UK-1 is highly virulent for chickens and mice.
Material and Methods
Bacterial strains and transformation of S. typhimurium. Salmonella typhimurium wildtype strain UK-1 was grown in Luria-Bertani (LB) medium. Cytokine-expressing plasmids (Bank for Cytokine Research, Korea) were transformed into E.coli DH5a. To form the transformed DH5a, plasmids were extracted and again transformed into S. typhimurium SF586. The plasmids which had formed the transformed SF586 were again transformed to S. typhimurium UK-1.
Bacterial challenges. Bacterial inocula of S. typhimurium were grown in Luria-Bertani (LB) medium to mid-log phase from single colonies. Bacteria were pelleted, resuspended in PBS, and quantified. Oral inoculation from a disposable syringe was used for oral challenges (10 3 -10 8 c.f.u. of bacteria in 100µl PBS). The mice were returned to cages with food and bedding and carefully monitored. They were killed if they became moribund. For bacterial translocation studies, the mice were treated as above, and 7 days after a single inoculation of 10 3 c.f.u, they were killed, their spleens were isolated and homogenized, and bacteria were plated in dilution on LB agar. Cytokine and antibody ELISA. Sera were collected by eye-bleeding 2 weeks after the last inoculation. Sera were assayed for detection of IL-12 with a commercially available kit (Endogen, Boston, MA), according to the manufacturer's directions. HRP-conjugated streptoavidin and tetramethylbenzydime were used in the cytokine ELISA. The absorbance was read on a Universal Microplate reader (EL800) at 630nm. Elisa was also used to assay antibody responses to S. typhimurium. Polystyrene 96-well flatbottom microtiter plates were coated with lysates of S. typhimurium (2 g per well).
Sera obtained from the same experimental group were pooled. A 100ul volume of diluted samples was added to individual wells in duplicate and incubated for 2h at 37 .
Plates were then washed and HRP-conjugated goat anti-mouse IgG and IgA which had been diluted 1:500 in blocking buffer were used as secondary antibodies.
Results

Efficient induction of immune response with DNA plasmids orally delivered by
Salmonella.
When eukaryotic expression plasmid-bearing S. typhimurium were fed to BALB/c mice, . Thus, all of the specific arms of the immune system should be induced. Fig. 1 shows that this was, indeed, the case. In mice that had been immunized with Salmonella transformants that carried expression plasmids encoding IL-12, More IL-12 induction in blood production than with wild-type salmonella control strain was detected.
Survival of wild-type S. typhimurium with cytokine-secreting plasmids.
To survival rate was obtained in mice infected orally with S. typhimurium strains (Fig. 2) .
Analysis of antibody responses to Salmonella following immunization with S. typhimurium UK-1 with IL-12 plasmids.
To see whether bacteria containing cytokine genes could be used as vaccines, we orally immunized mice with the 10 3 CFU of S. typhimurium UK-1 harboring cytokine plasmids. The serum sample was collected at 2, 4 weeks after immunization and tested for antibodies to S. typhimurium in the ELISA. Increased levels of serum IgG were detected in mice infected with S. typhimurium UK-1 harboring cytokine plasmids (Fig.   3A) . The specific response to the Salmonella antigen was also evaluated by measuring the specific antibody in the serum. The level of IgG in the serum was significantly higher in mice treated with Salmonella than in control mice. Additionally, an elevation of IgA anti-Salmonella levels was observed after the immunization in all experimental groups (Fig 3B. )
Proliferative responses to Salmonella antigen for Salmonella with IL-12 plasmids induced protection.
To evaluate the ability of S. typhimurium UK-1 with IL-12 plasmids to activate T lymphocytes, we cultured spleen cells of immunized animals and measured the proliferative response based on MTT-based assay. Salmonella with IL-12 plasmidprimed splenocytes proliferated in response to Salmonella lysate antigen or ConA stimulation (Fig. 4) . This finding demonstrates that Salmonella with IL-12 plasmids is able to activate primed murine T-cells more than non-transforming Salmonella that is a critical arm of the immune system involved in host protection against this parasitic infection.
Adjuvant effect of IL-12 on Salmonella with IL-12 plasmid-induced protection.
To In the present study, we transformed plasmids with the cytokine gene, but did not use general attenuation or modification processes. The process could be applied to develop vaccines against unknown pathogens, as it requi res neither characterization, nor genomic analysis. We used many cytokine genes for this Salmonella construction, selecting efficient strains harboring cytokine gene plasmids that induced protection in mice (data not shown). This wild-type pathogenic S. typhimurium UK1 harboring Il-12 expressing plasmids induced protection upon administration with a lethal dose (Fig. 5 ).
In the Salmonella harboring IL-12 plasmid vaccine model, IL-12 is involved in the protective response induced by administration and the level of protection is increased with co-administration of rIL-12.
In the present study, we showed the ability of wild-type S. typhimurium UK1 (20-100%) in presence of IL-12 to induce partial protection against challenge in mice.
The level of IL-12 which had increased more in blood following IL-12 administration is not the only mechanism involved in the enhanced protection observed in the S.
typhimurium with IL-12 immunized group. T-cell proliferative responses from these individuals to Salmonella with plasmids totally enhanced the responses and are dependent on IFN-gamma, which suggests a Th1 pattern of immune response in the control of this parasitic disease.
Although the vaccine presented here was not protective against challenge with high doses of pathogens, the safety problem and the effectiveness with higher doses could be overcome by lowering the dose of wild bacteria for immunization or by using plasmids expressing high concentrations of protein.
This investigation established that co-administration of IL-12expressing plasmids in the highly susceptible BALB/c mouse strain enhances survival against challenge with S.
typhimurium. The enhanced protective effect was accompanied by an increased production of IL-12 in blood-associated susceptibility and immunity against salmonellosis.
We also observed that the Salmonella harboring IL-12 plasmids induced antibody responses at low dose immunization, induced mucosal and humoral immunity, and showed protection (80-100%) against salmonellosis in mice, like other live attenuated vaccines.
In conclusion, we have shown in this study that IL-12 is an important cytokine for increasing protection induced by a Salmonella harboring IL-12 expressing plasmid administration strategy in mice. 
